Hepatitis C News and Research

Latest Hepatitis C News and Research

RDI launches HIV-TRePS system to predict patients’ response to HIV drugs

A ground-breaking system for predicting how individual patients with HIV and AIDS will respond to different drugs is launched today by RDI, a UK-based not-for-profit research group. The experimental system, called the HIV Treatment Response Prediction System (HIV-TRePS), is available free of charge over the Internet and helps physicians select the best treatment for their patients.

6 Oct 2010

Mass. hospital sale talks seeking to protect employee retirement plans; Conn. Gov. ask for waiver in preexisting insurance plan

Representatives of Caritas Christi Health Care, the private equity firm seeking to buy it, and the attorney general's office are working on a tentative agreement to protect the retirement plans of 13,000 employees and keep the chain's hospitals open for at least five years.

6 Oct 2010

Profectus BioSciences awarded $3.1M Fast Track SBIR grant to develop prophylactic vaccine against HIV

Profectus BioSciences, Inc., a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases, today announced the award of a Fast Track SBIR from the Division of AIDS, National Institutes of Health for $3.1M to support the development of the Company's Transition State Vaccine (TSV) technology for a prophylactic HIV Vaccine.

6 Oct 2010

Altravax receives two SBIR grants for antibody-inducing vaccines research on HIV-1

Altravax, Inc. announced today that it has been awarded two SBIR grants totaling $1.2 million from the NIH's National Institute of Allergy and Infectious Diseases for research on antibody-inducing vaccines for HIV-1.

6 Oct 2010

New approach method could simplify study and treatment of human diseases

Therapeutic antibodies can be an efficient alternative when common drugs do not work anymore. However, antibodies obtained from blood of animals such as mice could not be used: The human immune system recognizes them as foreign and rejects them.

6 Oct 2010

NSSHB study provides update on contemporary Americans' sexual behaviors

Findings from the largest nationally representative study of sexual and sexual-health behaviors ever fielded, conducted by Indiana University sexual health researchers, provides an updated and much needed snapshot of contemporary Americans' sexual behaviors, including a description of more than 40 combinations of sexual acts that people perform during sexual events, patterns of condom use by adolescents and adults, and the percentage of Americans participating in same-sex encounters.

5 Oct 2010

cobas TaqScreen DPX Test now available with CE Mark: Roche

Roche announced today that the cobas TaqScreen DPX Test for use on the cobas s 201 system is now available with the CE Mark. It is the first IVD test to offer complete coverage of all human genotypes of parvovirus B19 (B19V) and hepatitis A virus (HAV) in one assay.

5 Oct 2010

HGS receives Complete Response Letter from FDA for ZALBIN drug

Human Genome Sciences, Inc. today announced that, as expected, it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) for 900-mcg ZALBIN (albinterferon alfa-2b, known in Europe as JOULFERON®) dosed every two weeks for the treatment of chronic hepatitis C.

5 Oct 2010

Thomas Jefferson University Hospital commences live donor liver transplant program

The Division of Transplantation in the Department of Surgery at Thomas Jefferson University Hospital (TJUH) has started a live donor liver transplant program. Live donor liver transplantation (LDLT) is a procedure in which a living person donates a portion of his or her liver to another person. Combined, the two operations typically take about 12 hours. Since the program began in summer 2010, three patients and their donors have successfully undergone the procedure.

4 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

Benitec announces USPTO's reversal of all previous rejections in '099 Graham patent appeal

Benitec Limited, a leading Australian based company specialising in RNA interference (RNAi) technology is pleased to announce the United States Patent and Trademark Office's (USPTO) Board of Patent Appeals and Interferences decision ("the Decision") reversing all previous rejections in the US 6,573,099 (the '099 Graham patent) appeal.

4 Oct 2010

Bristol-Myers Squibb to present multiple compounds’ data at AASLD annual meeting

New data on multiple Bristol-Myers Squibb Company compounds will be presented at the 61st annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 29 to November 2.

3 Oct 2010

Herpevac Trial for Women finds experimental vaccine ineffective in prevention of genital herpes disease

An experimental vaccine intended to prevent genital herpes disease in women, although generally safe and well-tolerated, proved ineffective when tested in the recently concluded clinical study known as the Herpevac Trial for Women.

1 Oct 2010

Achillion initiates ACH-1625 Phase II dosing for HCV infection

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that the Company has initiated patient dosing in a Phase II clinical trial of ACH-1625 for the treatment of hepatitis C virus (HCV) infection. ACH-1625 is a potent small molecule inhibitor of HCV protease, an enzyme necessary for viral replication. The drug candidate was discovered and is being advanced by Achillion.

1 Oct 2010

Candidates who have strong religious connection have better post-transplant survival

Italian researchers report that liver transplant candidates who have a strong religious connection have better post-transplant survival. This study also finds that religiosity—regardless of cause of death—prolongs the life span of individuals who underwent liver transplantation.

1 Oct 2010

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.

30 Sep 2010

Researchers develop genetic screening method to identify drug-resistant HCV strains

In recent human trials for a promising new class of drug designed to target the hepatitis C virus (HCV) without shutting down the immune system, some of the HCV strains being treated exhibited signs of drug resistance.

30 Sep 2010

School blood test breached guidelines: Investigation report

According to a report by an Education Department, a Tasmanian teacher who conducted blood tests on 19 high school students breached guidelines. The incident happened last month when a teacher at the Dover District High School took blood samples from the students using just two lancets for a science class experiment. These lancets were cleaned between pricks using methylated spirits. These spirits are inadequate when preventing blood borne viral disease like HIV and Hepatitis say experts.

29 Sep 2010

ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial

ZymoGenetics, Inc. today announced positive survival data from a Phase 2a clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. Median overall survival was 12.4 months, and the percentage of patients surviving at 12 months was 53%.

29 Sep 2010

Florida likely to seek waiver on medical loss ratio; Ariz. cuts back Medicaid benefits

The Hill Healthwatch: "Florida's 14-member insurance advisory board has unanimously passed a resolution to seek a waiver from the health law's medical loss ratio. An official with the Florida Office of Insurance Regulation tells The Hill that the board's vote means it's a 'done deal' that the state will formally seek some kind of waiver but the board is gathering public input through Oct. 8.

29 Sep 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

RDI launches HIV-TRePS system to predict patients’ response to HIV drugs

Mass. hospital sale talks seeking to protect employee retirement plans; Conn. Gov. ask for waiver in preexisting insurance plan

Profectus BioSciences awarded $3.1M Fast Track SBIR grant to develop prophylactic vaccine against HIV

Altravax receives two SBIR grants for antibody-inducing vaccines research on HIV-1

New approach method could simplify study and treatment of human diseases

NSSHB study provides update on contemporary Americans' sexual behaviors

cobas TaqScreen DPX Test now available with CE Mark: Roche

HGS receives Complete Response Letter from FDA for ZALBIN drug

Thomas Jefferson University Hospital commences live donor liver transplant program

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Benitec announces USPTO's reversal of all previous rejections in '099 Graham patent appeal

Bristol-Myers Squibb to present multiple compounds’ data at AASLD annual meeting

Herpevac Trial for Women finds experimental vaccine ineffective in prevention of genital herpes disease

Achillion initiates ACH-1625 Phase II dosing for HCV infection

Candidates who have strong religious connection have better post-transplant survival

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Researchers develop genetic screening method to identify drug-resistant HCV strains

School blood test breached guidelines: Investigation report

ZymoGenetics announces positive survival data from IL-21 Phase 2a clinical trial

Florida likely to seek waiver on medical loss ratio; Ariz. cuts back Medicaid benefits

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in